Allogene Therapeutics, Inc. (ALLO) Stock
ALLO Key Statistics
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
CEO: David D. Chang. Company website
ALLO — Frequently Asked Questions
What is the ALLO stock price today?
Allogene Therapeutics, Inc. (ALLO) trades at $2.28, down 25.37% on the day, as of Sep 20, 2026 15:00 UTC.
What is Allogene Therapeutics, Inc.'s market cap?
Allogene Therapeutics, Inc. has a market capitalisation of $555.81M, calculated from the live ALLO share price and shares outstanding.
What is the P/E ratio of ALLO?
ALLO has no meaningful price-to-earnings ratio: Allogene Therapeutics, Inc. lost $0.87 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Allogene Therapeutics, Inc. make?
Allogene Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ALLO?
ALLO has traded between $2.06 and $4.46 over the past 52 weeks, and the last price is 48.9% below that high.
Is Allogene Therapeutics, Inc. profitable?
Yes. Allogene Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ALLO?
Wall Street analysts rate ALLO Buy, with an average price target of $6.43, 182.0% above the current price.
What sector is Allogene Therapeutics, Inc. in?
Allogene Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Allogene Therapeutics, Inc.?
David D. Chang is the chief executive of Allogene Therapeutics, Inc., which employs 226 people.
Where can I track ALLO in real time?
QFI Terminal shows ALLO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ALLO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ALLO in Terminal See plans